Bradykinin inhibits development of myocardial infarction through B 2 receptor signalling by increment of regional blood flow around the ischaemic lesions in rats

British Journal of Pharmacology

Volumn 138, Issue 1, 2003, Pages 225-233

  Ito, Hiroshi ^a   Hayashi, Izumi ^a   Izumi, Tohru ^a   Majima, Masataka ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bradykinin; Brown Norway Katholiek rats; FR190997; Hoe140; Myocardial infarction

Indexed keywords

8 [2,6 DICHLORO 3 [N [4 (N METHYLCARBAMOYL)CINNAMAMIDOACETYL] N METHYLAMINO]BENZYLOXY] 2 METHYL 4 (2 PYRIDYLMETHOXY)QUINOLINE; APROTININ; BRADYKININ; ICATIBANT; KALLIKREIN;

ACUTE HEART INFARCTION; ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; HEART INFARCTION SIZE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; MEAN ARTERIAL PRESSURE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT;

ANIMALS; BRADYKININ; CORONARY CIRCULATION; KININOGENS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; RATS; RATS, INBRED BN; RATS, SPRAGUE-DAWLEY; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ; SIGNAL TRANSDUCTION;

EID: 0037278313     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705013     Document Type: Article

References (39)

1. ARAMORI, I., ZENKOH, J., MORIKAWA, N., ASANO, M., HATORI, C., SAWAI, H., KAYAKIRI, H., SATOH, S., INOUE, T., ABE, Y., SAWADA, Y., MIZUTANI, T., INAMURA, N., NAKAHARA, K., KOJO, H., OKU, T. & NOTSU, Y. (1997). Nonpeptide mimic of bradykinin with long-acting properties at the bradykinin B2 receptor. Mol. Pharmacol., 52, 16-20.
2. BHOOLA, K.D., FIGUEROA, C.D. & WORTHY, K. (1992). Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol. Rev., 44, 1-80.
3. ERTL, G., KLONER, R.A., ALEXANDER, R.W. & BRAUNWALD, E. (1982). Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation, 65, 40-48.
4. FLEETWOOD, G., BOUTINET, S., MEIER, M. & WOOD, J.M. (1991). Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart. J. Cardiovasc. Pharmacol., 17, 351-356.
5. HAMILTON, K.L., POWERS, S.K., SUGIURA, T., KIM, S., LENNON, S., TUMER, N. & MEHTA, J.L. (2001). Short-term exercise training can improve myocardial tolerance to I/R without elevation in heat shock proteins. Am. J. Physiol. Heart Circ. Physiol., 281, H1346-H1352.
6. HARTMAN, J.C., WALL, T.M., HULLINGER, T.G. & SHEBUSKI, R.J. (1993). Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J. Cardiovasc. Pharmacol., 21, 996-1003.
7. HASHIMOTO, K., HIROSE, M., FURUKAWA, S., HAYAKAWA, H. & KIMURA, E. (1977). Changes in hemodynamics and bradykinin concentration in coronary sinus blood in experimental coronary artery occlusion. Jpn. Heart J., 18, 679-689.
8. HAYASHI, I., HOSHIKO, S., MAKABE, O. & OH-ISHI, S. (1993). A point mutation of alanine 163 to threonine is responsible for the defective secretion of high molecular weight kininogen by the liver of brown Norway Katholiek rats. J. Biol. Chem., 268, 17219-17224.
9. HOCK, C.E., RIBEIRO, L.G. & LEFER, A.M., (1985). Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction. Am. Heart J., 109, 222-228.
10. ITO, K., ZHU, Y.Z., ZHU, Y.C., GOHLKE, P. & UNGER, T. (1997). Contribution of bradykinin to the cardioprotective action of angiotensin converting enzyme inhibition in hypertension and after myocardial infarction. Jpn. J. Pharmacol., 75, 311-318.
11. KAUKER, M.L., CROFTON, J.T., SHARE, L. & NASJLETTI, A. (1984). Role of vasopressin in regulation of renal kinin excretion in Long-Evans and diabetes insipidus rats. J. Clin. Invest., 73, 824-831.
12. KOWALLIK, P., SCHULZ, R. & GUTH, B.D. (1991). Measurement of reginal myocardial blood flow with multiple colored microspheres. Circulation, 83, 974-982.
13. KURIBAYASHI, Y., KATORI, M., MAJIMA, M. & YOSHIDA, K. (1996). Inhibitory effects of a phosphate diester of alpha-tocopherol and ascorbic acid (EPC-K1) on myocardial infarction in rats. Int. J. Tissue React., 18, 73-79.
14. LIEM, D.A., VAN DEN DOEL, M.A., DE ZEEUW, S., VERDOUW, P.D. & DUNCKER, D.J. (2001). Role of adenosine in ischemic preconditioning in rats depends critically on the duration of the stimulus and involves both A(1) and A(3) receptors. Cardiovasc. Res., 51, 701-708.
15. LINZ, W., SCHOLKENS, B.A. & HAN, Y.F. (1986). Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J. Cardiovasc. Pharmacol., 8, S91-S99.
16. LINZ, W., WIEMER, G., GOHLKE, P., UNGER, T. & SCHOLKENS, B.A. (1995). Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev., 47, 25-49.
17. MAJIMA, M., HAYASHI, I., INAMURA, N., FUJITA, T. & OGINO, M. (2000). A nonpeptide mimic of bradykinin blunts the development of hypertension in young spontaneously hypertensive rats. Hypertension, 35, 437-442.
18. MAJIMA, M. & KATORI, M. (1995). Approaches to the development of novel antihypertensive drugs: crucial role of the renal kallikrein-kinin system. Trends Pharmacol. Sci., 16, 239-246.
19. MAJIMA, M., KATORI, M., HANAZUKA, M., MIZOGAMI, S., NAKANO, T., NAKAO, Y., MIKAMI, R., URYU, H., OKAMURA, R. & MOHSIN, S.S. (1991). Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system. Hypertension, 17, 806-813.
20. MAJIMA, M., NISHIYAMA, K., IGUCHI, Y., YAO, K., OGINO, M., OHNO, T., SUNAHARA, N., KATOH, K., TATEMICHI, N., TAKEI, Y. & KATORI, M. (1996). Determination of bradykinin-(1-5) in inflammatory exudate by a new ELISA as a reliable indicator of bradykinin generation. Inflamm. Res., 45, 416-423.
21. MAJIMA, M., YOSHIDA, O., MIHARA, H., MUTO, T., MIZOGAMI, S., KURIBAYASHI, Y., KATORI, M. & OH-ISHI, S. (1993). High sensitivity to salt in kininogen-deficient brown Norway Katholiek rats. Hypertension, 22, 705-714.
22. MARTORANA, P.A., KETTENBACH, B., BREIPOHL, G., LINZ, W. & SCHOLKENS, B. (1990). Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur. J. Pharmacol., 182, 395-396.
23. MATSUMURA, K., KOMORI, S., TAKUSAGAWA, M., OSADA, M., TANABE, F., ITOH, M. & TAMURA, K. (2000). Protein kinase C is involved in cardioprotective effects of ischemic preconditioning on infarct size and ventricular arrhythmia in rats in vivo. Mol. Cell Biochem., 214, 39-45.
24. MENASCHE, P., KEVELAITIS, E., MOUAS, C., GROUSSET, C., PIWNICA, A. & BLOCH, G. (1995). Preconditioning with potassium channel openers. A new concept for enhancing cardioplegic protection? J. Thorac. Cardiovasc. Surg., 110, 1606-1613.
25. MIURA, T., KAWAMURA, S., TATSUNO, H., IKEDA, Y., MIKAMI, S., IWAMOTO, H., OKAMURA, T., IWATATE, M., KIMURA, M., DAIRAKU, Y., MAEKAWA, T. & MATSUZAKI, M. (2001). Ischemic preconditioning attenuates cardiac sympathetic nerve injury via ATP-sensitive potassium channels during myocardial ischemia. Circulation, 104, 1053-1058.
26. NOLLY, H., CARBINI, L.A., SCICLI, G., CARRETERO, O.A. & SCICLI, A.G. (1994). A local kallikrein-kinin system is present in rat hearts. Hypertension, 23, 919-923.
27. NOLLY, H., CARRETERO, O.A. & SCICLI, A.G. (1993). Kallikrein release by vascular tissue. Am. J. Physiol,. 265, H1209-H1214.
28. PITT, B., MASON, J., CONTI, C.R. & COLMAN, R.W. (1969). Observations on the plasma kallikrein system during myocardial ischemia. Trans. Assoc. Am. Physicians, 82, 98-108.
29. SASAKI, K., UENO, A., KATORI, M. & KIKAWADA, R. (1988). Detection of leukotriene B4 in cardiac tissue and its role in infarct extension through leucocyte migration. Cardiovasc. Res., 22, 142-148.
30. SHARMA, A & SINGH, M. (2001). Protein kinase C activation and cardioprotective effect of preconditioning with oxidative stress in isolated rat heart. Mol. Cell Biochem., 219, 1-6.
31. SHINMURA, K., TANG, X.L., WANG, Y., XUAN, Y.T., LIU, S.Q., TAKANO, H., BHATNAGAR, A & BOLLI, R. (2000). Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc. Natl. Acad. Sci. U.S.A., 97, 10197-10202.
32. STEFANO, G.B., NEENAN, K., CADET, P., MAGAZINE, H. & BILFINGER, T.V. (2001). Ischemic preconditioning - an opiate constitutive nitric oxide molecular hypothesis. Med. Sci. Monit., 7, 1357-1375.
33. TOOMBS, C.F., MOORE, T.L. & SHEBUSKI, R.J. (1993). Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc. Res., 27, 617-622.
34. TSCHOPE, C., HERINGER-WALTHER, S., KOCH, M., SPILLMANN, F., WENDORF, M., LEITNER, E., SCHULTHEISS, H.P. & WALTHER, T. (2000). Upregulation of bradykinin B1-receptor expression after myocardial infarction. Br. J. Pharmacol., 129, 1537-1538.
35. VAN GILST, W.H., VAN WIJNGAARDEN, J., SCHOLTENS, E., DE GRAEFF, P.A., DE LANGEN, C.D, & WESSELING, H. (1987). Captopril-induced increase in coronary flow: an SH-dependent effect on arachidonic acid metabolism? J. Cardiovasc. Pharmacol., 9:S31-S36.
36. WIRTH, K., BREIPOHL, G., STECHL, J., KNOLLE, J., HENKE, S. & SCHOLKENS, B. (1991b). DesArg9-D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (desArg10-[Hoe140]) is a potent bradykinin B1 receptor antagonist. Eur. J. Pharmacol., 205, 217-218.
37. WIRTH, K., HOCK, F.J., ALBUS, U., LINZ, W., ALPERMANN, H.G., ANAGNOSTOPOULOS, H., HENK, S., BREIPOHL, G., KONIG, W. & KNOLLE, J. (1991a). Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol., 102, 774-777.
38. YANG, X.P., LIU, Y.H., SCICLI, G.M., WEBB, C.R. & CARRETERO, O.A. (1997). Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension, 30, 735-740.
39. YOSHIDA, H., ZHANG, J.J., CHAO, L. & CHAO, J. (2000). Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension, 35, 25-31.